KRAS EXON 2 MUTATION

外显子2突变与非小细胞肺癌和结直肠癌中对表皮生长因子受体抑制剂的应答率降低或耐药性有关。NCCN大肠癌指南中建议，靶向治疗西妥昔单抗和帕尼图单抗只能用于野生型KRA。
Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.